Clinical Trial Update: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Trimodulin (BT588) for severe community-acquired pneumonia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• Trimodulin (BT588)

Snippet

Sponsor: Biotest | Conditions: Community-acquired Pneumonia | Phase 3 | Status: RECRUITING